ComMedX

ComMedX (Computational Medicine Beijing Co., Ltd.), established in September 2020, is a platform company focused on computational chemistry-driven new drug discovery. Utilizing globally leading core technologies such as ultra-large-scale virtual screening based on protein three-dimensional structures and artificial intelligence, the company provides early-stage development services for small-molecule innovative drugs to pharmaceutical enterprises and research institutions worldwide. It rapidly identifies lead compounds to meet the urgent needs of small-molecule innovative drug discovery from 0 to 1. Our core technical team comes from the University of California, San Francisco, and the Beijing Institute of Life Sciences, hoping to promote the industrialization of scientific research achievements by integrating cutting-edge interdisciplinary technologies in biology, chemistry, pharmacy, computer science, and more, accelerating the development of original innovative drugs.